US firm 22nd Century Group plans to use its expertise in plant science, biotechnology and genetics to move further into cannabinoid production.
Announcing its full-year results for 2021, the company said it generated its first revenue from hemp/cannabis IP and plant lines in the fourth quarter of 2021.
Part of this came from a three-way non-exclusive licence of the Anandia biosynthesis IP (jointly owned with Aurora Cannabis) to Cronos Group, to assist in the advancement of biosynthetic cannabinoids
...Are you already a subscriber? login here
Need help?
Contact a sales representative right now and don’t wait
Erik Galavis
+34 654 320 547
Email Erik
Pablo Sharrock
+34 722 642 678
Email Pablo
